- Home
- TNON vs MBIO Comparison
TNON vs MBIO Comparison
Compare TNON & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNON
- MBIO
- Stock Information
- Founded
- TNON 2012
- MBIO 2015
- Country
- TNON United States
- MBIO United States
- Employees
- TNON N/A
- MBIO 80
- Industry
- TNON Medical Specialities
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- TNON Health Care
- MBIO Health Care
- Exchange
- TNON Nasdaq
- MBIO Nasdaq
- Market Cap
- TNON 6.7M
- MBIO 7.3M
- IPO Year
- TNON 2022
- MBIO N/A
- Fundamental
- Price
- TNON $1.79
- MBIO $5.55
- Analyst Decision
- TNON Strong Buy
- MBIO Strong Buy
- Analyst Count
- TNON 2
- MBIO 1
- Target Price
- TNON $16.00
- MBIO $2.00
- AVG Volume (30 Days)
- TNON 153.6K
- MBIO 468.6K
- Earning Date
- TNON 03-11-2025
- MBIO 03-10-2025
- Dividend Yield
- TNON N/A
- MBIO N/A
- EPS Growth
- TNON N/A
- MBIO N/A
- EPS
- TNON N/A
- MBIO N/A
- Revenue
- TNON $3,315,000.00
- MBIO N/A
- Revenue This Year
- TNON $29.03
- MBIO N/A
- Revenue Next Year
- TNON $100.29
- MBIO N/A
- P/E Ratio
- TNON N/A
- MBIO N/A
- Revenue Growth
- TNON 38.30
- MBIO N/A
- 52 Week Low
- TNON $1.65
- MBIO $5.19
- 52 Week High
- TNON $15.79
- MBIO $76.00
- Technical
- Relative Strength Index (RSI)
- TNON 39.49
- MBIO 31.43
- Support Level
- TNON $1.65
- MBIO $5.19
- Resistance Level
- TNON $2.30
- MBIO $13.30
- Average True Range (ATR)
- TNON 0.16
- MBIO 2.31
- MACD
- TNON 0.01
- MBIO -0.47
- Stochastic Oscillator
- TNON 21.57
- MBIO 2.14
About TNON Tenon Medical Inc.
Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities: 1) Primary SI Joint procedures, 2) Revision procedures of failed SI Joint implants, and 3) SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.